Experts suggest that taking GLP-1 medications for weight loss may enhance male fertility. At the ENDO 2026, the Endocrine Society’s annual event in Chicago, researchers discussed the strong link between obesity and fertility problems in men.
Obesity can disrupt the hypothalamic-pituitary-gonadal (HPG) axis, essential for testosterone regulation, leading to low testosterone levels and impacting semen quality. This condition, known as functional hypogonadism, often stems from hormone signaling issues.
Research Overview
The study examined the effects of GLP-1 weight-loss drugs on reproductive hormones and metabolic responses. Data from men aged 18 to 65 using these medications were analyzed through a review of five controlled trials. Key areas measured included testosterone levels, hormones influencing testosterone and sperm production, and proteins transporting sex hormones. The study also assessed semen quality, weight, BMI, cholesterol, and blood sugar levels.
The findings suggested that GLP-1 medications do not suppress male hormones. Men with obesity-related low testosterone might see improvements in testosterone, sperm quality, and metabolic health, especially when losing weight.
Key Findings from Trials
A four-week study on dulaglutide found no significant changes in reproductive hormones or sexual function. Conversely, a 16-week trial with liraglutide improved hormones in obese men with functional hypogonadism. Liraglutide showed better health outcomes than hormone replacement therapy. Another study noted increased sperm concentration and count with liraglutide.
GLP-1s appear not to suppress the male HPG axis and may enhance reproductive hormone function and sperm quality in obese men with hypogonadism.
A 24-week semaglutide trial revealed improvements in sperm shape and bad cholesterol levels while maintaining testosterone levels. Although the evidence base is small, researchers call for more extensive studies to explore the association further.
Expert Insights
Dr. Anthony Puopolo, a men’s health expert, emphasized GLP-1 medications’ potential in improving testosterone levels in obese men with low testosterone. While more research is necessary, Puopolo expressed optimism over GLP-1 medications as a preferable alternative to testosterone replacement therapy, which may harm reproductive function.

Cancer Death Rates Decline in the U.S., But Disparities Remain
COVID-19 Vaccine Study Highlights Effectiveness Amid Controversy
Life Inside Biocontainment and Updates on Covid-19 Vaccine Policies
Extreme Heat Risk Spreads Across the U.S.
Efforts to Address Hospice Fraud and Strengthen Program Integrity
CDC-Collected COVID-19 Vaccine Study Published Amid Methodological Debate